Tenon Medical Inc

TENON Medical, Inc. is a medical device company, which is designed to optimize sacroiliac joint fixation / fusion surgery and corresponding outcomes. The firm is preparing a national launch of this system to address the greatly underserved market opportunity that exists in this space. The company was founded on June 19, 2012 and is headquartered in Los Gatos, CA.

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Tenon Medical reports robust Q1 performance amidst profitability challenges

Tenon Medical Inc delivered strong financial and clinical results in Q1 2024, driven by revenue growth and positive clinical study outcomes for the Catamaran System.
While facing challenges in profitability and operating losses, the company's solid financial position, innovative product portfolio, and strategic focus on market expansion present opportunities for future growth.
To capitalize on its strengths and opportunities, Tenon Medical must address cost management, profitability concerns, and maintain a competitive edge in the market through innovation and strategic investments.

Tenon Medical Inc reports revenue growth and innovation focus in Q2 2024

Tenon Medical Inc's Q2 2024 performance reflects revenue growth and improved gross profit margins, underpinned by a strong focus on innovation and market expansion.
While facing challenges in managing operating expenses and achieving profitability, the company's financial position remains stable with no debt.
Opportunities lie in leveraging upcoming study results, expanding market presence, and optimizing operational efficiency to drive future growth and financial success.

Tenon Medical reports revenue growth and innovation drive amidst challenges

Tenon Medical Inc demonstrated strong revenue growth and margin improvement in Q3 2024, driven by the Catamaran System. Despite temporary revenue challenges, the company received funding for growth initiatives and product launches.
With a focus on innovation, patent issuance, and a capable CFO addition, Tenon Medical is poised for future success in the competitive medical technology market. Overcoming reimbursement hurdles and maintaining growth momentum are key focus areas.
The company's financial stability, lack of debt, and strategic initiatives position it well to capitalize on opportunities, expand its product offerings, and drive long-term value for shareholders and stakeholders.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Tenon Medical, Inc. is a medical device company, which engages in the development of a minimally invasive approach to the sacroiliac joint (SI joint) using a single titanium implant for treatment of the most common types of SI Joint disorders. The company was founded by Richard Ferrari and Richard Ginn on June 19, 2012 and is headquartered in Los Gatos, CA.

Mark H. Stouffer, MD and team from Zion Surgery Center perform first case in St George, UT. This clinical study will assess patient pain scores, fusion as well as other patient reported outcomes out to 24 months LOS GATOS, CA / ACCESSWIRE / November 15, 2022 / Tennon Medical, Inc. ("Tenon" or the "Company") (NASDAQ:TNON), a company transforming care for patients suffering with certain sacroiliac joint disorders, today announced completion of the first patient treated in the Company's Catamaran SI Joint Fusion System clinical study.

Tenon Medical Announces Treatment of First Patient in Strategic Post Market Clinical Study with Company's Catamaran(TM) SI Joint Fusion System

~ Revenue up 197% year-over-year ~ ~ Subsequent to Quarter End, National Launch of the Catamaran ™ SI Joint Fusion System at NASS ~ LOS GATOS, CA / ACCESSWIRE / November 10, 2022 / Tenon Medical, Inc. (NASDAQ:TNON) ("Tenon Medical" or the "Company"), a company transforming care for patients suffering with certain sacroiliac disorders, today reported financial results for the third quarter ended September 30, 2022. Recent Highlights National launch of the Catamaran™ SI Joint Fusion System (the "Catamaran") at the North American Spine Society (NASS) meeting (Chicago, IL), October 12-15, 2022, with a technical exhibit, interactive surgeon training sessions, and outcomes from a single center experience with the Catamaran presented at an Innovative Technology Session Received Institutional Review Board ("IRB") approval from WCG IRB for two separate Tenon-sponsored post market clinical studies of Catamaran which allows designated Catamaran study centers to begin recruiting and enrolling patients into the respective studies Modified our National Distribution arrangement allowing accelerated commercial scale with the development of Tenon Medical commercial infrastructure and sales management to support top line growth 100 surgical procedures utilizing Catamaran completed in the pre-launch phase 71 physicians have completed a Catamaran workshop as of November 1, 2022 Revenue of $208,000 in the third quarter of 2022, an 197% increase from the same period in 2021, and a 54% increase on a sequential basis compared to the second quarter 2022 Recently released CMS final rule for code 27279 increases 2023 Medicare facility fee by approximately 26% for SI joint fusion procedures performed in ASCs and 33% for these procedures done in hospital outpatient settings "We had multiple significant advancements for Catamaran in the third quarter to move us along our commercialization pathway," said Steve Foster, CEO and President of Tenon Medical.

Tenon Medical, Inc. Reports Third Quarter 2022 Financial Results

LOS GATOS, CA / ACCESSWIRE / November 2, 2022 / Tenon Medical, Inc. (NASDAQ:TNON) ("Tenon Medical" or the "Company"), a company transforming care for patients suffering with certain sacroiliac disorders, today announced management's participation in the following upcoming conferences: Q4 Investor Summit, November 14-15, 2022. Steven Foster, Chief Executive Officer, and Steven Van Dick, Chief Financial Officer, will present at 9:30 a.m.

Tenon Medical, Inc. Announces Participation in Upcoming Conferences

~ Feasibility and CT scan studies will assess patient pain scores, fusion as well as other patient reported outcomes out to 12 and 24 months ~ ~ Studies represent Tenon's continued commitment in validating and differentiating patient outcomes with Catamaran System~ LOS GATOS, CA / ACCESSWIRE / October 25, 2022 / Tenon Medical, Inc. ("Tenon" or the "Company") (NASDQ:TNON), a company transforming care for patients suffering with certain sacroiliac joint disorders, today announced Institutional Review Board ("IRB") approval from WCG IRB for two separate Tenon-sponsored post market clinical studies of the Company's Catamaran SI Joint Fusion System (the "Catamaran"). The approval by WCG represents a milestone for Tenon, which allows designated Catamaran study centers to begin recruiting and enrolling patients into the respective studies.

Tenon Medical's Catamaran(TM) SI Joint Fusion System Receives Institutional Review Board Approval for Two Strategic Post Market Studies

Los Gatos, California--(Newsfile Corp. - October 14, 2022) - Tenon Medical, Inc. (NASDAQ: TNON) ("Tenon Medical" or the "Company"), a company transforming care for patients suffering with certain sacroiliac disorders, today announced management's participation in the LD Micro Main Event XV conference being held from October 25-27, 2022 at the Luxe Sunset Boulevard Hotel in Bel Air, California.

Tenon Medical, Inc. Announces Participation in LD Micro Main Event XV Conference

~Company to launch Catamaran nationally at NASS with technical exhibit and interactive surgeon training sessions~ ~ Outcomes from a single center experience with the Catamaran to be presented at Innovative Technology Session, October 13th ~ LOS GATOS, CA / ACCESSWIRE / October 12, 2022 / Tenon Medical, Inc. ("Tenon" or the "Company") (NASDQ:TNON), a company transforming care for patients suffering with certain sacroiliac disorders, today announced the Company's attendance and planned activities at the37th Annual Meeting of the North American Spine Society (NASS), being held in Chicago from October 12 -15, 2022. The NASS meeting is attended by over 3,500 spine specialists-orthopedic surgeons, neurosurgeons, radiologists, and other health care providers.

Tenon Medical to Showcase Company's Catamaran(TM) SI Joint Fusion System at the 2022 North American Spine Society 37th Annual Meeting

~ Tenon reaches amicable termination with exclusive distributor partner, SpineSource ~ ~ SpineSource to support transition over 6-month period ~ LOS GATOS, CA / ACCESSWIRE / October 11, 2022 / Tenon Medical, Inc. ("Tenon" or the "Company") (NASDAQ:TNON), a company transforming care for patients suffering with certain sacroiliac disorders, today announced the termination of its national distribution agreement with distribution partner, SpineSource, for the Company's Catamaran™ SI Joint Fusion System. The termination of the exclusive partnership comes following the Company's April Initial Public Offering ("IPO") and supports acceleration of its commercial scale and investment to achieve its revenue growth targets.

Tenon Medical Accelerates Commercial Scale with Own Infrastructure to Support Top Line Growth, Terminates National Distribution Agreement for Company's Catamaran(TM) SI Joint Fusion System

LOS GATOS, CA / ACCESSWIRE / September 14, 2022 / Tenon Medical, Inc. (NASDAQ:TNON) ("Tenon Medical" or the "Company"), a medical device company that has developed a proprietary, U.S. Food and Drug Administration ("FDA") cleared surgical implant system for sacroiliac joint ("SI Joint") fixation/fusion surgery, today announced that management will present during Benzinga's All Access investor event taking place Friday, September 16, 2022. Steve Foster, Chief Executive Officer of Tenon Medical, is scheduled to host a presentation and Q&A session during the event as follows.

Tenon Medical, Inc. to Present at Benzinga All Access Event on Friday, September 16, 2022

LOS GATOS, CA / ACCESSWIRE / August 24, 2022 / Tenon Medical, Inc. (NASDAQ:TNON) ("Tenon Medical" or the "Company"), a medical device company that has developed a proprietary, U.S. Food and Drug Administration ("FDA") cleared surgical implant system for sacroiliac joint ("SI Joint") fixation/fusion surgery, today announced its virtual participation in the following conferences: H.C. Wainwright 24th Annual Global Investment Conference, September 12 - September 14, 2022 A.G.P.

Tenon Medical, Inc. Announces Upcoming Virtual Conference Participation

Blue Water Vaccines

Genius Group Ltd

Golden Sun Education Group Ltd

AMTD Digital

JE Cleantech Holdings Ltd

Magic Empire Global Ltd

Ostin Technology Group Co Ltd

Yoshitsu Co Ltd

Visionary Education Technology Holdings Group Inc

WeTrade Group Inc

So far in 2022, IPO activity has been dominated by small, volatile issuers. Of the 19 IPOs with 100%+ pops, 17 have traded down from the first-day close, and 11 trade below issue.

2022 IPOs With The Largest First-Day Pops Are Now Some Of The Worst Performers

~ Revenue increases 514% year-over-year ~ ~ 21 physician workshop events completed ~ LOS GATOS, CA/ ACCESSWIRE / August 11, 2022 / Tenon Medical, Inc. (NASDAQ:TNON) ("Tenon Medical" or the "Company"), a medical device company that has developed a proprietary, U.S. Food and Drug Administration ("FDA") cleared surgical implant system for sacroiliac joint ("SI Joint") fixation/fusion surgery, today reported financial results for the second quarter ended June 30, 2022. Recent Highlights Ongoing early commercialization of the Catamaran™ SI Joint Fusion System with a full launch to coincide with the North American Spine Society (NASS) meeting (Chicago, IL), October 12-15, 2022 As of August 11, 2022, the Company hosted 21 physician workshop events Revenue of $135,000 in the second quarter of 2022, a 514% increase from the same period in 2021, and an 90% increase on a sequential basis compared to the first quarter 2022 Closed $16 Million Initial Public Offering ("IPO") on April 29, 2022 Company's common stock commenced trading on the Nasdaq Capital Markets under the ticker symbol "TNON" "The second quarter of 2022 was highlighted by increasing momentum on our commercialization pathway, supported by the addition of new capital from our transition to a public company," commented Steve Foster, CEO and President of Tenon Medical.

Tenon Medical, Inc. Reports Second Quarter 2022 Financial Results

Bausch Health Companies Inc

Bausch + Lomb Corp

Medtronic

Meihua International Medical Technologies Co

Virax Biolabs Group Ltd

At least one group is bullish about the outlook for the medtech industry: venture capitalists.

Investors May Want to Follow Progress of VC-Backed Medtechs

~ Closes $16 Million IPO and Commences Trading on the Nasdaq ~ LOS GATOS, CA / ACCESSWIRE / June 7, 2022 / Tenon Medical, Inc. ("Tenon Medical" or the "Company"), a medical device company that has developed a proprietary, U.S. Food and Drug Administration ("FDA") cleared surgical implant system for sacroiliac joint ("SI Joint") fixation/fusion surgery, today reported financial results for the quarter ended March 31, 2022. Recent Highlights Closes $16 Million Initial Public Offering ("IPO") on April 29, 2022 Company's common stock commenced trading on the Nasdaq Capital Markets under the ticker symbol "TNON" Initial commercialization commencement of the Catamaran SIJ Fusion System Revenue of $71,000 in the first quarter of 2022, a 373% increase from the same period in 2021 As of March 31, 2022, the Company hosted 9 physician workshop events "Tenon Medical kicked off 2022 achieving a tremendous milestone with our transition to a public company listing on the Nasdaq Capital Markets subsequent to quarter end," commented Steve Foster, CEO and President of Tenon Medical.

Tenon Medical, Inc. Reports First Quarter 2022 Financial Results

Ontrak

Regulus Therapeutics

Can these penny stocks make gains next month? The post Top Penny Stocks to Buy Now?

Top Penny Stocks to Buy Now? 3 to Watch in June 2022

News for Tenon Medical Inc Stock (TNON)